Mounjaro 15 mg Price – KwikPen Injection for Type 2 Diabetes Management and Weight Reduction
Drug presentation
Mounjaro 15 mg is a once-weekly injectable medication supplied in a pre-filled KwikPen device. It contains tirzepatide, an innovative molecule that simultaneously activates GIP and GLP-1 receptors, two key hormones involved in blood sugar regulation and appetite control.
By enhancing insulin secretion, slowing gastric emptying, and reducing hunger signals, Mounjaro helps improve glycemic control and supports significant weight loss in adults with type 2 diabetes when lifestyle measures alone are not sufficient.
Dosage and administration
Mounjaro 15 mg is administered once per week by subcutaneous injection.
• Injection sites include the abdomen, upper arm, or thigh.
• One KwikPen contains four weekly injections, each delivering 0.6 ml of solution.
• The 15 mg dose is typically the highest step in the titration schedule, introduced after gradual increases to improve tolerance.
• It may be prescribed alone or combined with other antidiabetic treatments such as metformin, insulin, or sulfonylureas, depending on the patient’s treatment plan.
Price and availability
The average price of Mounjaro 15 mg is approximately €480 per KwikPen, which includes four weekly doses (one month of treatment).
At present, the medication is not reimbursed by the French public health insurance system, although certain private health insurance plans may provide partial reimbursement.
Therapeutic indications and advantages
Mounjaro 15 mg is primarily prescribed for:
• Adults with type 2 diabetes requiring improved glycemic control
• Patients struggling with weight management associated with metabolic disease
Potential benefits include:
• Reduction in HbA1c levels
• Weight loss that may reach 15% or more of initial body weight in some patients
• Better satiety and appetite regulation
• Improved metabolic health and long-term diabetes management
Possible side effects
Most adverse effects occur during dose escalation and tend to be temporary.
Common reactions include:
• Nausea or vomiting
• Digestive discomfort (diarrhea or constipation)
• Reduced appetite
• Mild fatigue or dizziness
Rare but serious events may include pancreatitis or hypersensitivity reactions, requiring immediate medical attention.
Safety precautions
Before starting treatment, patients should follow several precautions:
• Do not use Mounjaro during pregnancy or breastfeeding.
• Always inform your healthcare provider of other medications you are taking.
• Store the pen in the refrigerator between 2°C and 8°C and avoid freezing.
• Once in use, the pen should be handled according to the manufacturer’s storage recommendations.
Patient experience
“Since starting Mounjaro, my glucose readings are much more stable and my appetite is easier to control. I’ve lost several kilograms without feeling constantly hungry.
Frequently asked questions
Is Mounjaro 15 mg used only for diabetes?
Yes. It is primarily approved for type 2 diabetes treatment, although weight loss is a significant additional benefit.
When can results be expected?
Blood sugar improvements are usually noticeable within the first month, while weight reduction typically appears after two to three months of regular treatment.
Do I need a prescription to obtain Mounjaro 15 mg?
Yes. Mounjaro KwikPen is a prescription-only medication and must be used under medical supervision.
Related products
MOUNJARO
MOUNJARO
MOUNJARO
MOUNJARO
MOUNJARO